By characterizing metabolic and immune microenvironment reveal potential prognostic markers in the development of colorectal cancer

Colon adenocarcinoma (COAD) is one of the deadliest cancers in the world and survival rates vary significantly between early and advanced stage patients. Therefore, the identification of the pathogenesis in the development of COAD and prognostic markers is urgently demanded. Herein, we collected RNA...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in bioengineering and biotechnology Vol. 10; p. 822835
Main Authors Liao, Liangliang, Gao, Yongjian, Su, Jie, Feng, Ye
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 05.08.2022
Subjects
Bioengineering and Biotechnology
clinical stages
metabolic and immune
prognostic markers
somatic mutation
transcriptional regulation
Online AccessGet full text

Cover

More Information
Summary:Colon adenocarcinoma (COAD) is one of the deadliest cancers in the world and survival rates vary significantly between early and advanced stage patients. Therefore, the identification of the pathogenesis in the development of COAD and prognostic markers is urgently demanded. Herein, we collected RNA-seq and somatic mutation data of COAD for statistical analysis. Clinical stage-specific differentially expressed genes (DEGs) and tumor development-dependent DEGs were identified. By characterizing the metabolic and immune features of COAD between stages, we found that the energy supply and inflammatory response of advanced tumors were suppressed. Next, the ETS1, AR, GATA1, GATA2, SREBF1, FOXP3, STAT4, and NFKB1 were identified to drive the metabolic and immune-related pathways in the development of COAD. The three potential prognostic markers ( HOXC8, IRF7, and CXCL13 ) were identified based on Cox regression analysis. Additionally, immune infiltration analysis revealed that the resting CD4 + T cell was significantly related to the overall survival (OS) of COAD patients. Collectively, the specific metabolic and immune characteristics of advanced patients and the identified prognostic biomarkers will contribute to the development of precision medicine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
This article was submitted to Preclinical Cell and Gene Therapy, a section of the journal Frontiers in Bioengineering and Biotechnology
Reviewed by: Nguyen Quoc Khanh Le, Taipei Medical University, Taiwan
Giulia Russo, University of Catania, Italy
These authors share first authorship
Edited by: Ping Zhang, Griffith University, Australia
ISSN:2296-4185
2296-4185
DOI:10.3389/fbioe.2022.822835